These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 8104070

  • 21. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation.
    Ho AD, Haas R, Korbling M, Dietz M, Hunstein W.
    Bone Marrow Transplant; 1991; 7 Suppl 1():13-7. PubMed ID: 1675138
    [Abstract] [Full Text] [Related]

  • 22. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood.
    To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage RE.
    Exp Hematol; 1990 Jun; 18(5):442-7. PubMed ID: 1970963
    [Abstract] [Full Text] [Related]

  • 23. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
    Tarella C, Boccadoro M, Omedé P, Bondesan P, Caracciolo D, Frieri R, Bregni M, Siena S, Gianni AM, Pileri A.
    Bone Marrow Transplant; 1993 Apr; 11(4):271-7. PubMed ID: 7683551
    [Abstract] [Full Text] [Related]

  • 24. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
    Glück S, Ross AA, Layton TJ, Ostrander AB, Goldstein LC, Porter K, Ho AD.
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
    [Abstract] [Full Text] [Related]

  • 25. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F, Cavenaghi L, de Melo CM.
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [Abstract] [Full Text] [Related]

  • 26. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
    Lefrère F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, Hermine O, Damaj G, Maillard N, Ribeil JA, Azagury M, Misbahi R, Jondeau K, Cavazzana-Calvo M, Dal Cortivo L, Varet B.
    Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
    [Abstract] [Full Text] [Related]

  • 27. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sánchez-Cortés E, Ayala-Sánchez M, Guevara-Moreno ME, García-León LD, Rosas-Cabral A, Esparza MA, González-Llaven J.
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [Abstract] [Full Text] [Related]

  • 28. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
    Annunziata M, Celentano M, Pocali B, D'Amico MR, Palmieri S, Viola A, Copia C, Falco C, Del Vecchio L, Ferrara F.
    Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
    [Abstract] [Full Text] [Related]

  • 29. Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children.
    Kawano Y, Takaue Y, Watanabe T, Saito S, Abe T, Hirao A, Sato J, Ninomiya T, Suzue T, Koyama T.
    Exp Hematol; 1993 Jan; 21(1):103-8. PubMed ID: 7678082
    [Abstract] [Full Text] [Related]

  • 30. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH, Christiansen NP, Fay JP, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP.
    Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
    [Abstract] [Full Text] [Related]

  • 31. Effect of cytokine treatment (granulocyte colony-stimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice.
    Drize N, Chertkov J, Samoilina N, Zander A.
    Exp Hematol; 1996 Jun; 24(7):816-22. PubMed ID: 8647232
    [Abstract] [Full Text] [Related]

  • 32. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G, Patoia L, Giglietti A, Alessio M, Pelicci P, Grignani F.
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [Abstract] [Full Text] [Related]

  • 33. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
    Gómez-Espuch J, Moraleda JM, Ortuño F, Lozano ML, Ayala F, Vallejo C, de Arriba F, Vicente V.
    Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
    [Abstract] [Full Text] [Related]

  • 34. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
    Lefrere F, Makke J, Fermand J, Marolleau J, Dal Cortivo L, Alberti C, Mouton V, Benbunan M, Miclea J.
    Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
    [Abstract] [Full Text] [Related]

  • 35. Blood stem cell collections in multiple myeloma: definition of a scoring system.
    Corso A, Caberlon S, Pagnucco G, Klersy C, Zappasodi P, Alessandrino EP, Vanelli L, Mangiacavalli S, Lazzarino M, Bernasconi C.
    Bone Marrow Transplant; 2000 Aug; 26(3):283-6. PubMed ID: 10967566
    [Abstract] [Full Text] [Related]

  • 36. G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).
    Joffe JK, Bell JB, Denham S, Adshead F, Millar JL, Millar BC.
    Exp Hematol; 1995 Apr; 23(4):376-82. PubMed ID: 7534716
    [Abstract] [Full Text] [Related]

  • 37. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT, Zeller W, Stockschläder M, Krüger W, Hoffknecht MM, Zander AR.
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [Abstract] [Full Text] [Related]

  • 38. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS, Lee KB.
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [Abstract] [Full Text] [Related]

  • 39. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P, Delain M, Desbois I, Domenech J, Binet C, Tabah I, Lamagnere JP, Linassier C.
    Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
    [Abstract] [Full Text] [Related]

  • 40. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N, McGlave P.
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.